Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Cancer. 2021 Apr 7;127(13):2251–2261. doi: 10.1002/cncr.33483

Figure 1.

Figure 1.

(A) All-site recurrence-free survival and (B) isolated nodal basin recurrence-free survival are illustrated by performance of completion lymph node dissection (CLND) versus active surveillance (Surv) and (C,D) by receipt of adjuvant (adj) systemic therapy. Log-rank tests were stratified by location of the treating center (Australia, Europe, United States). HR indicates hazard ratio.